Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 204,336 |
|
|||||
| News | - | ||||||
| Day High | 19.725 | Low High |
|||||
| Day Low | 17.425 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Celcuity Inc | CELC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.06 | -0.35% | 17.17 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 19.47 | 17.425 | 19.725 | 17.66 | 17.23 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,583 | 204,336 | $ 18.27 | $ 3,733,722 | - | 8.389 - 22.188 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:47:42 | 1 | $ 17.92 | USD |
Celcuity Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 426.7M | 24.20M | - | 0 | -63.78M | -2.64 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Celcuity News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CELC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 17.76 | 19.725 | 16.39 | 16.96 | 160,331 | -0.59 | -3.32% |
| 1 Month | 16.99 | 19.725 | 14.63 | 16.81 | 228,085 | 0.18 | 1.06% |
| 3 Months | 14.98 | 22.188 | 14.63 | 17.79 | 252,471 | 2.19 | 14.62% |
| 6 Months | 12.14 | 22.188 | 11.79 | 16.62 | 194,841 | 5.03 | 41.43% |
| 1 Year | 9.00 | 22.188 | 8.389 | 14.84 | 135,093 | 8.17 | 90.78% |
| 3 Years | 26.85 | 33.01 | 4.81 | 14.51 | 87,263 | -9.68 | -36.05% |
| 5 Years | 21.32 | 33.01 | 4.03 | 16.41 | 76,572 | -4.15 | -19.47% |
Celcuity Description
| Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR). |
